The secondary use of electronic health records for data mining: Data characteristics and challenges
The primary objective of implementing Electronic Health Records (EHRs) is to improve the
management of patients' health-related information. However, these records have also been …
management of patients' health-related information. However, these records have also been …
Cellular and molecular mechanisms of metformin: an overview
B Viollet, B Guigas, NS Garcia, J Leclerc… - Clinical …, 2012 - portlandpress.com
Considerable efforts have been made since the 1950s to better understand the cellular and
molecular mechanisms of action of metformin, a potent antihyperglycaemic agent now …
molecular mechanisms of action of metformin, a potent antihyperglycaemic agent now …
[HTML][HTML] Pathophysiologic approach to therapy in patients with newly diagnosed type 2 diabetes
RA DeFronzo, R Eldor, M Abdul-Ghani - Diabetes care, 2013 - ncbi.nlm.nih.gov
Two general approaches to the treatment of type 2 diabetes mellitus (T2DM) have been
advocated. 1) A “guideline” approach that advocates sequential addition of antidiabetes …
advocated. 1) A “guideline” approach that advocates sequential addition of antidiabetes …
Impact of glucose-lowering drugs on cardiovascular disease in type 2 diabetes
E Ferrannini, RA DeFronzo - European heart journal, 2015 - academic.oup.com
Type 2 diabetes mellitus (T2DM) is characterized by multiple pathophysiologic
abnormalities. With time, multiple glucose-lowering medications are commonly required to …
abnormalities. With time, multiple glucose-lowering medications are commonly required to …
Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial …
TK Schramm, GH Gislason, A Vaag… - European heart …, 2011 - academic.oup.com
Aims The impact of insulin secretagogues (ISs) on long-term major clinical outcomes in type
2 diabetes remains unclear. We examined mortality and cardiovascular risk associated with …
2 diabetes remains unclear. We examined mortality and cardiovascular risk associated with …
Mortality risk among sulfonylureas: a systematic review and network meta-analysis
SH Simpson, J Lee, S Choi, B Vandermeer… - The lancet Diabetes & …, 2015 - thelancet.com
Background Sulfonylureas are common second-line options for management of type 2
diabetes; however, they are associated with a higher risk of cardiovascular events compared …
diabetes; however, they are associated with a higher risk of cardiovascular events compared …
Comparative effectiveness of sulfonylurea and metformin monotherapy on cardiovascular events in type 2 diabetes mellitus: a cohort study
Background: The effects of sulfonylureas and metformin on outcomes of cardiovascular
disease (CVD) in type 2 diabetes are not well-characterized. Objective: To compare the …
disease (CVD) in type 2 diabetes are not well-characterized. Objective: To compare the …
Sulfonylureas and the risks of cardiovascular events and death: a methodological meta-regression analysis of the observational studies
Recent randomized trials have compared the newer antidiabetic agents to treatments
involving sulfonylureas, drugs associated with increased cardiovascular risks and mortality …
involving sulfonylureas, drugs associated with increased cardiovascular risks and mortality …
Diabetes in older people
GS Meneilly, A Knip, DB Miller, D Sherifali… - Canadian journal of …, 2018 - Elsevier
This guideline refers primarily to type 2 diabetes in the older person. There is limited
information on the management of type 1 diabetes in the elderly, but this is included …
information on the management of type 1 diabetes in the elderly, but this is included …
[HTML][HTML] Place of sulfonylureas in the management of type 2 diabetes mellitus in South Asia: a consensus statement
S Kalra, AH Aamir, A Raza, AK Das… - Indian journal of …, 2015 - journals.lww.com
Since their introduction in clinical practice in the 1950's, Sulfonylureas (SUs) have remained
the main-stay of pharmacotherapy in the management of type 2 diabetes. Despite their well …
the main-stay of pharmacotherapy in the management of type 2 diabetes. Despite their well …